Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

Obesity-associated inflammation is a systemic process that affects all metabolic organs.
Prominent among these is adipose tissue, where cells of the innate and adaptive immune …

Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

Background Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in
obesity. We aimed to evaluate the effects of injectable liraglutide 3· 0 mg daily on body fat …

Cardiovascular diseases (CVDs) remain a leading cause of death worldwide. Among the
major risk factors for CVD, obesity and diabetes mellitus have received considerable …

Atherosclerotic cardiovascular disease (CVD) remains the leading cause of mortality
worldwide. While conventional risk factors have been studied and managed, CVD continues …

The obesity pandemic is accompanied by increased risk of develo** metabolic syndrome
(MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic …

Abstract Purpose of Review To discuss evidence supporting the use of glucagon-like
peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective …

Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …